Table 1.
Baseline characteristics of the included studies.
| Study | Regimen∗ | Duration (weeks) | Genotype | n | Age (mean) | Male (%) | Prior HCV treatment (%) | Cirrhosis (%) | Viral load | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Naïve | Experienced | HCV RNA log10 IU/mL (mean) | HCV RNA ≥ 800,000 IU/mL (%) | ||||||||
| Lawitz et al. [29] | SOF + PR | 12 | 5 | 1 | — | — | 100 | 0 | — | — | — |
| SOF + PR | 12 | 6 | 6 | — | — | 100 | 0 | — | — | — | |
| Kowdley et al. [27] | SOF + PR | 24 | 6 | 5 | — | — | 100 | 0 | 0 | - | — |
| Gane et al. [24] | SOF/LDV | 12 | 6 | 25 | 51 | 64 | 92 | 8 | 8 | 6.7 | — |
| Curry et al. [21] | SOF/VEL | 24 | 6 | 1 | 67 | 100 | 100 | 0 | 100 | 6.5 | 100 |
| Everson et al. [22] | SOF/VEL | 12 | 6 | 5 | 54 | 80 | 100 | 0 | 0 | 6.7 | 80 |
| SOF/VEL | 12 | 6 | 4 | 57 | 100 | 25 | 75 | 100 | |||
| 25 mg∗∗ | 6.1 | 75 | |||||||||
| Feld et al. [23] | SOF/VEL | 12 | 5 | 35 | — | — | — | — | — | — | — |
| SOF/VEL | 12 | 6 | 41 | — | — | — | — | — | — | — | |
| Gane et al. [25] | SOF/VEL/VOX | 8 | 6 | 1 | — | — | 100 | 0 | 100 | — | — |
| SOF/VEL/VOX | 12 | 6 | 2 | — | — | 0 | 100 | 50 | — | — | |
| Abergel et al. [20] | SOF/LDV | 12 | 5 | 41 | — | 51 | 51 | 49 | 22 | — | — |
| Lai et al. [28] | SOF + RBV | 12 | 6 | 3 | — | — | 100 | 0 | — | — | — |
| SOF + RBV | 16 | 6 | 4 | — | — | 100 | 0 | — | — | — | |
| SOF + RBV | 24 | 6 | 4 | — | — | 100 | 0 | — | — | — | |
| Jacobson et al. [26] | SOF/VEL/VOX | 8 | 5 | 18 | — | — | — | — | — | — | — |
| SOF/VEL/VOX | 8 | 6 | 30 | — | — | — | — | — | — | — | |
| SOF/VEL | 12 | 6 | 9 | — | — | — | — | — | — | — | |
| Nguyen et al. [30] | SOF/LDV | 8 | 6 | 20 | 57 | 55 | 100 | 0 | 0 | 6.2 | — |
| SOF/LDV | 12 | 6 | 40 | 59 | 60 | 62 | 38 | 68 | 6.6 | — | |
| Wei et al. [32] | SOF + PR | 12 | 6 | 32 | 38 | 47 | 69 | 31 | 6 | 6.5 | 84 |
| SOF + RBV | 24 | 6 | 4 | 36 | 75 | 50 | 50 | 0 | 6.4 | 50 | |
| Thuy et al. [31] | SOF/LDV | 12 | 6 | 86 | 52 | 47 | 92 | 8 | 2 | 6.7 | 63 |
| SOF/LDV + RBV | 12 | 6 | 39 | 59 | 39 | 33 | 67 | 56 | 6.7 | 85 | |
| SOF/LDV | 24 | 6 | 20 | 63 | 30 | 65 | 35 | 90 | 6.5 | 70 | |
| SOF/LDV + RBV | 24 | 6 | 30 | 64 | 40 | 70 | 30 | 97 | 6.7 | 82 | |
SOF, sofosbuvir; VEL, velpatasvir; LDV, ledipasvir; VOX, voxilaprevir; PR, PegIFN + ribavirin; RBV, ribavirin. ∗Standard dose of each drug is as follows: SOF, 400 mg per day; VEL, 100 mg per day; LDV, 90 mg per day; VOX, 100 mg per day; PegIFN 180 μg per week; RBV 1000–1200 mg per day. ∗∗Standard dose of VEL is 100 mg per day. In this study (Everson 2005), a VEL dose of 25 mg per day was experimented.